Monte Rosa Therapeutics/$GLUE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
- Ticker
- $GLUE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 173
- Headquarters
- Boston, United States
- Website
- www.monterosatx.com
GLUE Metrics
BasicAdvanced
$897M
-
-$1.74
1.50
-
Price and volume
Market cap
$897M
Beta
1.5
52-week high
$25.77
52-week low
$8.94
Average daily volume
1.3M
Financial strength
Current ratio
10.584
Quick ratio
10.494
Long term debt to equity
0.068
Total debt to equity
0.078
Profitability
EBITDA (TTM)
-173.728
Gross margin (TTM)
-465.18%
Net profit margin (TTM)
-560.85%
Operating margin (TTM)
-633.04%
Effective tax rate (TTM)
1.74%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
-21.63%
Return on equity (TTM)
-42.66%
Valuation
Price to revenue (TTM)
33.812
Price to book
1.84
Price to tangible book (TTM)
1.84
Price to free cash flow (TTM)
-30.28
Free cash flow yield (TTM)
-3.30%
Free cash flow per share (TTM)
-0.347
Growth
Revenue change (TTM)
-83.86%
Earnings per share change (TTM)
-693.12%
3-year earnings per share growth (CAGR)
-12.20%
What the Analysts think about GLUE
Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.
Analyst projections of the future price of Monte Rosa Therapeutics stock.
Bulls say / Bears say
MRT-8102’s Phase 1 study showed 80–90% NEK7 degradation and sharp falls in several inflammation markers, including an 85% median reduction in hsCRP. Adverse-event rates were similar to placebo, with no serious events reported. (BioSpace)
Novartis has started a Phase 2 study of MRT-6160 in Sjögren’s disease, advancing Monte Rosa’s partnered programme and triggering a $50 million milestone payment when the first patient visits. Earlier Phase 1 results showed more than 90% VAV1 degradation in T cells. (GlobeNewswire)
Monte Rosa reported $626 million in cash and marketable securities at the end of June and expects this to fund operations into 2029. That gives it time to advance several clinical programmes without an immediate need to raise more capital. (Nasdaq)
MRT-8102’s encouraging results are early biomarker findings, not proof that the drug prevents heart attacks or strokes. The Phase 1 study involved four weeks of dosing, so the benefit still needs validation in longer, larger trials. (Clinical Trial Vanguard, BioSpace)
Monte Rosa does not control the pace of MRT-6160’s Phase 2 development: Novartis is running and funding those studies, while the headline $2.1 billion in potential milestones depends on future development and commercial progress. Monte Rosa may also have to co-fund Phase 3 and share US profits and losses. (Nasdaq)
The MRT-2359 Phase 2 study is based on early results from only six patients with AR mutations in a prior Phase 1/2 group. The new study plans to enrol up to 25 patients, so the evidence for benefit in this selected prostate-cancer group remains limited. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2026.
GLUE Financial Performance
Revenues and expenses
GLUE Earnings Performance
Company profitability
Upcoming events
No upcoming events
GLUE News
AllArticlesVideos
Funds containing GLUE
AllUSDGBPEUR
Fund name | Fund size | $GLUE weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.03% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.